Drug Alerts and FDA News

 

2017

  • 07/26/2017 The FDA approved an important change to the Fycompa (perampanel) prescribing information. Perampanel is now approved as monotherapy for patients 12 years of age and older who have partial (focal)-onset seizures both with and without progression to generalized tonic-clonic seizures. This new, expanded FDA indication does not include monotherapy for primary generalized tonic-clonic seizures, where perampanel is still approved as adjunctive treatment. This is the first antiepileptic drug (AED) to receive approval for monotherapy use under the FDA's new rule granting a monotherapy indication based solely on the results of randomized controlled trials of adjunctive therapy for partial (focal)-onset seizures.
  • 03/28/2017 The FDA announced an update to the Vimpat (lacosamide) prescribing information to include a warning about rare cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS; formerly known as multiorgan hypersensitivity). Additionally, cardiogenic shock has been added as an effect of Vimpat overdose. More information is available here.
  • 03/07/2017 The FDA sent a letter to Sunovion asking that Prescribing Information be updated to include the occurrence of toxic epidermal necrolysis (TEN) with the use of Aptiom. This is in addition to the warnings of Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRWSS) listed in the current Prescribing Information. More here.
  • 02/20/2017 VistaPharm, Inc is recalling more than 12,000 units of Phenytoin Oral Suspension, USP 100 mg/ 4 mL, 50 unit dose cups of 4 mL per case, Rx only, according to the US Food and Drug Administration’s (FDA) latest Drug Enforcement Report (February 15, 2017).  The recall was initiated on January 18, 2017 due to, 'CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia,' according to the FDA.  The affected products were distributed throughout the United States. Known lot numbers include 428700 (Exp. 11/17) and 409500 (Exp. 06/17). On February 2, 2017, the FDA designated the recall a class II, meaning that exposure might cause temporary health problems, but is unlikely to cause injuries of a serious nature.
  • 02/07/2017 Health Canada has published a review that concluded that there may be a link between the use of levetiracetam (Keppra) and the risk of acute kidney injury. The current product information for Keppra informs that cases of acute kidney injury have been reported in patients treated with levetiracetam. Health Canada has requested that the other manufacturers of levetiracetam-containing products also update their product information with the same wording. More information is available here.

  • 01/05/2017 The FDA has issued a new class warning for the use of benzodiazepines concomitantly with opiates. This would include AEDs such as Onfi (clobazam), Klonopin (clonazepam), Ativan (lorazepam), Diastat (rectal diazepam) and others. The warning states, "concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.' Please see the attached prescribing information regarding Onfi (clobazam)." More information here and here. Find Onfi prescribing information here.

2016

  • 12/12/2016 Health Canada carried out a safety review after learning that the European Medicines Agency was looking into a potential interaction between levetiracetam and methotrexate. The interaction between the two drugs may lead to higher amount of methotrexate in the blood, which may cause serious side effects. The side effects, which can be fatal, include sudden (acute) kidney failure.
  • 11/18/2016 FDA recalls of Clonazepam Tablets, USP, 0.5 mg, a drug used to treat certain seizure and panic disorders. The recall affects certain packages. More information here.
  • 11/7/2016 Health Canada has indicated a potential link to respiratory depressionincluding sedation, somnolence, and loss of consciousnessin patients treated with gabapentin, particularly in patients having lung, kidney, or nervous system diseases that impact breathing, as well as in those that are elderly, or using other drugs that can affect breathing such as opioids, or in those are at higher risk of serious breathing problems. Additional information concerning the risk of respiratory depression has been added to the Warnings and Precautions section of the Canadian product monograph (CPM) for Neurontin (gabapentin). Concomitant use of CNS depressants with gabapentin is also a contributing factor. More information here.
  • 10/18/2016 EMA recommends measures to ensure safe use of Keppra oral solution. More information here.
  • 10/17/2016 FDA approves Carnexiv - i.v. carbamazepine, marketed by Lundbeck. More information here.
  • 10/6/2016 FDA recalls lamotrigine tablets, USP, 150 mg, due to misprinted tablets. The medication (NDC 29300-113-05) was packaged in 500-count bottles. More information here.
  • 9/26/2016 Zarontin (ethosuximide) - Defective Capsules Associated with Reduced Efficacy (Increased Frequency of Seizures). More information here.
  • 8/31/2016 Levetiracetam may rarely be associated with acute renal failure. Recently, the Ministry of Health, Labour, and Welfare in Japan reported that a patient treated with levetiracetam developed acute renal failure within 90 days of the initiation of the treatment. The condition resolved after discontinuation of levetiracetam. In Japan, the prescribing information for levetiracetam now lists acute renal failure as one of the serious adverse reactions. Currently, no specific monitoring is recommended with levetiracetam, but obtaining baseline renal tests before initiation of levetiracetam and periodically thereafter could be done to assess renal function.
  • 8/30/2016 Lamotrigine Orally Disintegrating Tablet 200 mg by Impax: Recall - Incorrect Labeling of Blister Cards. More information here.
  • 8/16/2016 GlaxoSmithKline (GSK) is advising healthcare providers that POTIGA (ezogabine) Tablets, CV, 50mg, 200mg, 300mg and 400mg will no longer be commercially available after June 30, 2017. GSK intends to permanently discontinue the product due to the very limited usage of the medicine and the continued decline in new patient initiation. Discontinuation is not due to efficacy or safety reasons. Read more. [PDF]
  • 8/15/2016 In an enforcement letter the week of August 1st, the FDA ordered a recall of Divalproex 100 mg delayed-release tablets manufactured by Teva, Inc. due to failed specifications. The recall number is D-1449-2016 and code information is Lot #: 02D163, Exp. 9/2017.
  • 5/29/2016 A new boxed warning has been added to the prescribing information for ezogabine: "Potiga (ezogabine) can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss. Macular abnormalities characterized as vitelliform lesions have also been observed. All patients taking Potiga should have baseline and periodic (every 6 months) systematic visual monitoring by an ophthalmic professional. Testing should include visual acuity, dilated fundus photography, and optical coherence tomography." Click here to download. [PDF]
  • 4/18/2016 Study in Neurology  finds pregabalin may be linked to major birth defects. View the Pubmed citation
  • 4/12/2016 The FDA issues overview, "FDA Regulation of Marijuana: Past Actions, Future Plans." Click here to download. [PDF]
  • 4/6/2016 The FDA and the manufacturer updated the prescribing information for Zonegran (zonisamide) to include a warning about Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) also known as multiorgan hypersensitivity. Download the revised prescribing information here. [PDF]
  • 2/19/2016 FDA approves Briviact (brivaracetam) as an add-on treatment to other medications to treat partial-onset seizures in patients age 16 years and older with epilepsy. Click here for more information.

2015

  • 12/21/2015 Drug interactions between AEDs and antivirals for hepatitis C. Recently, new antivirals (e.g., asunaprevir, daclatasvir, sofosbuvir, telaprevir, vaniprevir) and the endothelin receptor antagonist (macitenta) were approved for the treatment of hepatitis C. AEDs which induce the CYP3A4 isozyme (e.g., phenobarbital and phenytoin) increase the metabolism of antivirals, causing a significant reduction of the serum concentrations of the antivirals and the endothelin receptor antagonist. The antivirals and the endothelin receptor antagonist, with interferon, are necessary to eradicate the hepatitis C virus. Clinicians should be aware of this serious drug-drug interaction to optimize hepatitis C treatment. Providers are advised to consult with a pharmacist or use appropriate drug information resources to check any potential drug-drug interactions between AEDs and hepatitis C treatment agents.
  • 12/4/2015 On Dec 4, 2015, the FDA approved updated Prescribing Information (PI) for Oxtellar (oxcarbazepine). Serious, potentially life-threatening, dermatologic reactions such as toxic epidermal necrolysis (TEN) and Stevens Johnson syndrome (SJS) have occurred in adults and children treated with oxcarbazepine. Median time of onset was 19 days. Patients with Human Leukocyte Antigen (HLA) allele B*1502 may be at increased risk.  The HLA-B*1502 allele is present in 2-15% of patients from various countries with Han Chinese ancestry. Prior to initiating oxcarbazepine treatment, testing for  HLA-B*1502 should be considered in patients of Asian ancestry. Oxcarbazepine should be avoided in patients positive for HLA-B*1502, unless the benefits clearly outweigh the risks. Click here for the prescribing information. [PDF]
  • 9/30/2015 On August 28, 2015, the FDA approved updated Prescribing Information (PI) for Tegretol (carbamazepine). Information about the risk of serious dermatologic reactions such as toxic epidermal necrolysis (TEN) and Stevens Johnson syndrome (SJS) are presented. Among patients of Chinese ancestry, there is a strong association of developing SJS/TEN with the HLA-B*1502 gene variant. Prior to initiating Tegretol treatment, testing for  HLA-B*1502 should be performed in patients with ancestry in which HLA-B*1502 may be present (many Asian countries). The PI now states Tegretol should not be used in patients positive for HLA-B*1502 unless the benefit clearly outweighs the risks. Please see the full PI for additional information about this, as well as the use carbamazepine with other drugs such as phenytoin which may increase the risk of cutaneous reactions in patients with HLA-B*1502, the risks of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and the risk of SJS/TEN and DRESS among patients of European, Korean, Japanese and other ancestry who carry the HLA-A*3101 allelic variant. Click here for the prescribing information. [PDF]
  • 9/28/2015- The FDA and Pfizer issued an updated PI for Neurontin (gabapentin) in September 2015. The update is to section 5.2 of the PI which states "Neurontin can cause anaphylaxis and angioedema after the first dose or at any time during treatment. Signs and symptoms in reported cases have included difficulty breathing, swelling of the lips, throat and tongue and hypotension requiring emergency treatment. Patients should be instructed to discontinue Neurontin and seek immediate medical care should they experience signs and symptoms of anaphylaxis or angioedema."  Click here to download the prescribing information. [PDF]
  • 8/28/2015 - FDA approved a monotherapy indication for eslicarbazepine. The indication reads, "Aptiom (eslicarbazepine acetate) is indicated for the treatment of partial-onset seizures as monotherapy or adjunctive therapy." The recommended maintenance dose is 800 mg to 1600 mg once daily, depending on clinical response and tolerability. Click here to download the prescribing information. [PDF]
  • 6/19/2015 - FDA approved perampanel (Fycompa) for the adjunctive treatment of Primary Generalized Tonic-Clonic Seizures (PGTCS) in patients age 12 years and older. 
  • 6/17/2015 - FDA Determines Ezogabine Labeling Adequate to Manage Risks Based on reviews of additional safety reports from patients treated with the anti-seizure drug ezogabine (brand name Potiga), the US Food and Drug Administration has determined that the potential risks of vision loss due to pigment changes in the retina and of skin discoloration can be adequately managed by following the current recommendations in the ezogabine labeling. To further explore any potential long-term consequences of these pigment changes, FDA has required the ezogabine manufacturer, GlaxoSmithKline, to conduct a long-term observational study.  The FDA recommends that health care professionals should continue to follow the recommendations provided in the Boxed Warning, FDA’s most serious type of warning, and the Warnings and Precautions and Indications and Usage sections of the labeling.
  • 6/16/2015 - The FDA has worked with the manufacturer of fosphenytoin (Cerebyx) to update the prescribing information. Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding CEREBYX as an alternative for carbamazepine patients positive for HLAB*1502.
  • 5/22/2015  IV Levetiracetam – Shortage identified May 21, 2015   Earliest anticipated release date: June 2015
  • 5/7/2015  IV Valproate Sodium – Shortage identified May 7, 2015    Earliest anticipated release date: Late May 2015 
  • 4/20/2015 - Blue Cross Blue Shield Association has changed its policy to state that responsive neurostimulation may be considered medically necessary for patients with medication-refractory partial epilepsy who meet certain criteria. 
  • 3/25/2015 - Depakote PI update - "On March 10th, the FDA and the manufacturer updated the label for divalproex (Depakote) to include new and updated warnings about cytopenias, coagulopathies, and DRESS. The new prescribing information reads in section 5.8, 'Valproate is associated with dose-related thrombocytopenia ... and  ... decreases in other cell lines and myelodysplasias.  Because of reports of cytopenia, inhibition of secondary phase of platelet aggregation, and abnormal coagulation parameters (e.g., low fibrinogen, coagulation factor deficiencies, acquired VonWillebrand's disease) measurements of complete blood counts and coagulation parameters are recommended before initiating therapy and at periodic intervals.' In addition in section 5.12, the term Multi-organ Hypersensitivity Reaction has been changed to Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and a completely revised description of DRESS and its severity is provided along with recommendations on how to evaluate it and to stop Depakote." The March 2015 PI is attached here and is also available on the FDA website.
  • 3/17/2015 -  Levetiracetam (Keppra) - The FDA, working with the manufacturer, has updated the prescribing information for levetiracetam (Keppra). New warnings include behavioral abnormalities and psychotic symptoms, somnolence and fatigue, red blood cell and white blood cell count decreases, as well as significant diastolic blood pressure increases in 17% of children aged 1 month to <4 years. Read more.
  • 3/11/2015 - The US Food & Drug Administration, working with the manufacturer, has made changes to the prescribing information (PI) for Vimpat with regard to overdoses with the medication. The updated PI contains the wording, 'Following single acute overdoses of 1,000 mg or greater of Vimpat, cardiac conduction disorders and seizures, including generalized tonic-clonic seizures and status epilepticus have been observed.'  The updated PI can be found here.

Past FDA News, Updates, & Press Announcements

Reported drug shortages

<html xmlns="http://www.w3.org/1999/xhtml" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office">
  <head>
  <!-- NAME: RIGHT SIDEBAR -->
  <!--[if gte mso 15]>
  <xml>
  <o:OfficeDocumentSettings>
  <o:AllowPNG/>
  <o:PixelsPerInch>96</o:PixelsPerInch>
  </o:OfficeDocumentSettings>
  </xml>
  <![endif]-->
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>*|MC:SUBJECT|*</title>
   
  <style type="text/css">
  p{
  margin:10px 0;
  padding:0;
  }
  table{
  border-collapse:collapse;
  }
  h1,h2,h3,h4,h5,h6{
  display:block;
  margin:0;
  padding:0;
  }
  img,a img{
  border:0;
  height:auto;
  outline:none;
  text-decoration:none;
  }
  body,#bodyTable,#bodyCell{
  height:100%;
  margin:0;
  padding:0;
  width:100%;
  }
  #outlook a{
  padding:0;
  }
  img{
  -ms-interpolation-mode:bicubic;
  }
  table{
  mso-table-lspace:0pt;
  mso-table-rspace:0pt;
  }
  .ReadMsgBody{
  width:100%;
  }
  .ExternalClass{
  width:100%;
  }
  p,a,li,td,blockquote{
  mso-line-height-rule:exactly;
  }
  a[href^=tel],a[href^=sms]{
  color:inherit;
  cursor:default;
  text-decoration:none;
  }
  p,a,li,td,body,table,blockquote{
  -ms-text-size-adjust:100%;
  -webkit-text-size-adjust:100%;
  }
  .ExternalClass,.ExternalClass p,.ExternalClass td,.ExternalClass div,.ExternalClass span,.ExternalClass font{
  line-height:100%;
  }
  a[x-apple-data-detectors]{
  color:inherit !important;
  text-decoration:none !important;
  font-size:inherit !important;
  font-family:inherit !important;
  font-weight:inherit !important;
  line-height:inherit !important;
  }
  #bodyCell{
  padding:10px;
  }
  .templateContainer{
  max-width:600px !important;
  }
  a.mcnButton{
  display:block;
  }
  .mcnImage{
  vertical-align:bottom;
  }
  .mcnTextContent{
  word-break:break-word;
  }
  .mcnTextContent img{
  height:auto !important;
  }
  .mcnDividerBlock{
  table-layout:fixed !important;
  }
  /*
  @tab Page
  @section Background Style
  @tip Set the background color and top border for your email. You may want to choose colors that match your company's branding.
  */
  body,#bodyTable{
  /*@editable*/background-color:#f7f7f7;
  }
  /*
  @tab Page
  @section Background Style
  @tip Set the background color and top border for your email. You may want to choose colors that match your company's branding.
  */
  #bodyCell{
  /*@editable*/border-top:0;
  }
  /*
  @tab Page
  @section Email Border
  @tip Set the border for your email.
  */
  .templateContainer{
  /*@editable*/border:0;
  }
  /*
  @tab Page
  @section Heading 1
  @tip Set the styling for all first-level headings in your emails. These should be the largest of your headings.
  @style heading 1
  */
  h1{
  /*@editable*/color:#202020;
  /*@editable*/font-family:Helvetica;
  /*@editable*/font-size:26px;
  /*@editable*/font-style:normal;
  /*@editable*/font-weight:bold;
  /*@editable*/line-height:125%;
  /*@editable*/letter-spacing:normal;
  /*@editable*/text-align:left;
  }
  /*
  @tab Page
  @section Heading 2
  @tip Set the styling for all second-level headings in your emails.
  @style heading 2
  */
  h2{
  /*@editable*/color:#202020;
  /*@editable*/font-family:Helvetica;
  /*@editable*/font-size:22px;
  /*@editable*/font-style:normal;
  /*@editable*/font-weight:bold;
  /*@editable*/line-height:125%;
  /*@editable*/letter-spacing:normal;
  /*@editable*/text-align:left;
  }
  /*
  @tab Page
  @section Heading 3
  @tip Set the styling for all third-level headings in your emails.
  @style heading 3
  */
  h3{
  /*@editable*/color:#202020;
  /*@editable*/font-family:Helvetica;
  /*@editable*/font-size:20px;
  /*@editable*/font-style:normal;
  /*@editable*/font-weight:bold;
  /*@editable*/line-height:125%;
  /*@editable*/letter-spacing:normal;
  /*@editable*/text-align:left;
  }
  /*
  @tab Page
  @section Heading 4
  @tip Set the styling for all fourth-level headings in your emails. These should be the smallest of your headings.
  @style heading 4
  */
  h4{
  /*@editable*/color:#202020;
  /*@editable*/font-family:Helvetica;
  /*@editable*/font-size:18px;
  /*@editable*/font-style:normal;
  /*@editable*/font-weight:bold;
  /*@editable*/line-height:125%;
  /*@editable*/letter-spacing:normal;
  /*@editable*/text-align:left;
  }
  /*
  @tab Preheader
  @section Preheader Style
  @tip Set the background color and borders for your email's preheader area.
  */
  #templatePreheader{
  /*@editable*/background-color:#FAFAFA;
  /*@editable*/background-image:none;
  /*@editable*/background-repeat:no-repeat;
  /*@editable*/background-position:center;
  /*@editable*/background-size:cover;
  /*@editable*/border-top:0;
  /*@editable*/border-bottom:0;
  /*@editable*/padding-top:9px;
  /*@editable*/padding-bottom:9px;
  }
  /*
  @tab Preheader
  @section Preheader Text
  @tip Set the styling for your email's preheader text. Choose a size and color that is easy to read.
  */
  #templatePreheader .mcnTextContent,#templatePreheader .mcnTextContent p{
  /*@editable*/color:#656565;
  /*@editable*/font-family:Helvetica;
  /*@editable*/font-size:12px;
  /*@editable*/line-height:150%;
  /*@editable*/text-align:left;
  }
  /*
  @tab Preheader
  @section Preheader Link
  @tip Set the styling for your email's preheader links. Choose a color that helps them stand out from your text.
  */
  #templatePreheader .mcnTextContent a,#templatePreheader .mcnTextContent p a{
  /*@editable*/color:#656565;
  /*@editable*/font-weight:normal;
  /*@editable*/text-decoration:underline;
  }
  /*
  @tab Header
  @section Header Style
  @tip Set the background color and borders for your email's header area.
  */
  #templateHeader{
  /*@editable*/background-color:#FFFFFF;
  /*@editable*/background-image:none;
  /*@editable*/background-repeat:no-repeat;
  /*@editable*/background-position:center;
  /*@editable*/background-size:cover;
  /*@editable*/border-top:0;
  /*@editable*/border-bottom:0;
  /*@editable*/padding-top:0;
  /*@editable*/padding-bottom:0;
  }
  /*
  @tab Header
  @section Header Text
  @tip Set the styling for your email's header text. Choose a size and color that is easy to read.
  */
  #templateHeader .mcnTextContent,#templateHeader .mcnTextContent p{
  /*@editable*/color:#202020;
  /*@editable*/font-family:Helvetica;
  /*@editable*/font-size:16px;
  /*@editable*/line-height:150%;
  /*@editable*/text-align:left;
  }
  /*
  @tab Header
  @section Header Link
  @tip Set the styling for your email's header links. Choose a color that helps them stand out from your text.
  */
  #templateHeader .mcnTextContent a,#templateHeader .mcnTextContent p a{
  /*@editable*/color:#2BAADF;
  /*@editable*/font-weight:normal;
  /*@editable*/text-decoration:underline;
  }
  /*
  @tab Sidebar
  @section Sidebar Style
  @tip Set the background color and borders for your email's sidebar.
  */
  #templateSidebar{
  /*@editable*/background-color:#eeeeee;
  /*@editable*/border-top:0;
  /*@editable*/border-bottom:0;
  /*@editable*/padding-top:0;
  /*@editable*/padding-bottom:2px;
  }
  /*
  @tab Sidebar
  @section Sidebar Text
  @tip Set the styling for your email's sidebar text. Choose a size and color that is easy to read.
  */
  #templateSidebar .mcnTextContent,#templateSidebar .mcnTextContent p{
  /*@editable*/color:#424242;
  /*@editable*/font-family:Helvetica;
  /*@editable*/font-size:12px;
  /*@editable*/line-height:150%;
  /*@editable*/text-align:left;
  }
  /*
  @tab Sidebar
  @section Sidebar Link
  @tip Set the styling for your email's sidebar links. Choose a color that helps them stand out from your text.
  */
  #templateSidebar .mcnTextContent a,#templateSidebar .mcnTextContent p a{
  /*@editable*/color:#843179;
  /*@editable*/font-weight:normal;
  /*@editable*/text-decoration:underline;
  }
  /*
  @tab Body
  @section Body Style
  @tip Set the background color and borders for your email's body.
  */
  #templateBody,#templateColumns{
  /*@editable*/background-color:#FFFFFF;
  /*@editable*/border-top:0;
  /*@editable*/border-bottom:0;
  /*@editable*/padding-top:0;
  /*@editable*/padding-bottom:2px;
  }
  /*
  @tab Body
  @section Body Text
  @tip Set the styling for your email's body text. Choose a size and color that is easy to read.
  */
  #templateBody .mcnTextContent,#templateBody .mcnTextContent p{
  /*@editable*/color:#202020;
  /*@editable*/font-family:Helvetica;
  /*@editable*/font-size:16px;
  /*@editable*/line-height:150%;
  /*@editable*/text-align:left;
  }
  /*
  @tab Body
  @section Body Link
  @tip Set the styling for your email's body links. Choose a color that helps them stand out from your text.
  */
  #templateBody .mcnTextContent a,#templateBody .mcnTextContent p a{
  /*@editable*/color:#843179;
  /*@editable*/font-weight:normal;
  /*@editable*/text-decoration:underline;
  }
  /*
  @tab Footer
  @section Footer Style
  @tip Set the background color and borders for your email's footer area.
  */
  #templateFooter{
  /*@editable*/background-color:#fafafa;
  /*@editable*/background-image:none;
  /*@editable*/background-repeat:no-repeat;
  /*@editable*/background-position:center;
  /*@editable*/background-size:cover;
  /*@editable*/border-top:2px solid #EAEAEA;
  /*@editable*/border-bottom:0;
  /*@editable*/padding-top:2px;
  /*@editable*/padding-bottom:2px;
  }
  /*
  @tab Footer
  @section Footer Text
  @tip Set the styling for your email's footer text. Choose a size and color that is easy to read.
  */
  #templateFooter .mcnTextContent,#templateFooter .mcnTextContent p{
  /*@editable*/color:#656565;
  /*@editable*/font-family:Helvetica;
  /*@editable*/font-size:12px;
  /*@editable*/line-height:150%;
  /*@editable*/text-align:center;
  }
  /*
  @tab Footer
  @section Footer Link
  @tip Set the styling for your email's footer links. Choose a color that helps them stand out from your text.
  */
  #templateFooter .mcnTextContent a,#templateFooter .mcnTextContent p a{
  /*@editable*/color:#656565;
  /*@editable*/font-weight:normal;
  /*@editable*/text-decoration:underline;
  }
  @media only screen and (min-width:768px){
  .templateContainer{
  width:600px !important;
  }
   
  } @media only screen and (max-width: 480px){
  body,table,td,p,a,li,blockquote{
  -webkit-text-size-adjust:none !important;
  }
   
  } @media only screen and (max-width: 480px){
  body{
  width:100% !important;
  min-width:100% !important;
  }
   
  } @media only screen and (max-width: 480px){
  #bodyCell{
  padding-top:10px !important;
  }
   
  } @media only screen and (max-width: 480px){
  #templateSidebar,#templateBody{
  max-width:100% !important;
  width:100% !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnImage{
  width:100% !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnCartContainer,.mcnCaptionTopContent,.mcnRecContentContainer,.mcnCaptionBottomContent,.mcnTextContentContainer,.mcnBoxedTextContentContainer,.mcnImageGroupContentContainer,.mcnCaptionLeftTextContentContainer,.mcnCaptionRightTextContentContainer,.mcnCaptionLeftImageContentContainer,.mcnCaptionRightImageContentContainer,.mcnImageCardLeftTextContentContainer,.mcnImageCardRightTextContentContainer{
  max-width:100% !important;
  width:100% !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnBoxedTextContentContainer{
  min-width:100% !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnImageGroupContent{
  padding:9px !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnCaptionLeftContentOuter .mcnTextContent,.mcnCaptionRightContentOuter .mcnTextContent{
  padding-top:9px !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnImageCardTopImageContent,.mcnCaptionBlockInner .mcnCaptionTopContent:last-child .mcnTextContent{
  padding-top:18px !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnImageCardBottomImageContent{
  padding-bottom:9px !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnImageGroupBlockInner{
  padding-top:0 !important;
  padding-bottom:0 !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnImageGroupBlockOuter{
  padding-top:9px !important;
  padding-bottom:9px !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnTextContent,.mcnBoxedTextContentColumn{
  padding-right:18px !important;
  padding-left:18px !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcnImageCardLeftImageContent,.mcnImageCardRightImageContent{
  padding-right:18px !important;
  padding-bottom:0 !important;
  padding-left:18px !important;
  }
   
  } @media only screen and (max-width: 480px){
  .mcpreview-image-uploader{
  display:none !important;
  width:100% !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Heading 1
  @tip Make the first-level headings larger in size for better readability on small screens.
  */
  h1{
  /*@editable*/font-size:22px !important;
  /*@editable*/line-height:125% !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Heading 2
  @tip Make the second-level headings larger in size for better readability on small screens.
  */
  h2{
  /*@editable*/font-size:20px !important;
  /*@editable*/line-height:125% !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Heading 3
  @tip Make the third-level headings larger in size for better readability on small screens.
  */
  h3{
  /*@editable*/font-size:18px !important;
  /*@editable*/line-height:125% !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Heading 4
  @tip Make the fourth-level headings larger in size for better readability on small screens.
  */
  h4{
  /*@editable*/font-size:16px !important;
  /*@editable*/line-height:150% !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Boxed Text
  @tip Make the boxed text larger in size for better readability on small screens. We recommend a font size of at least 16px.
  */
  .mcnBoxedTextContentContainer .mcnTextContent,.mcnBoxedTextContentContainer .mcnTextContent p{
  /*@editable*/font-size:14px !important;
  /*@editable*/line-height:150% !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Preheader Visibility
  @tip Set the visibility of the email's preheader on small screens. You can hide it to save space.
  */
  #templatePreheader{
  /*@editable*/display:block !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Preheader Text
  @tip Make the preheader text larger in size for better readability on small screens.
  */
  #templatePreheader .mcnTextContent,#templatePreheader .mcnTextContent p{
  /*@editable*/font-size:14px !important;
  /*@editable*/line-height:150% !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Header Text
  @tip Make the header text larger in size for better readability on small screens.
  */
  #templateHeader .mcnTextContent,#templateHeader .mcnTextContent p{
  /*@editable*/font-size:16px !important;
  /*@editable*/line-height:150% !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Sidebar Text
  @tip Make the sidebar text larger in size for better readability on small screens. We recommend a font size of at least 16px.
  */
  #templateSidebar .mcnTextContent,#templateSidebar .mcnTextContent p{
  /*@editable*/font-size:16px !important;
  /*@editable*/line-height:150% !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Body Text
  @tip Make the body text larger in size for better readability on small screens. We recommend a font size of at least 16px.
  */
  #templateBody .mcnTextContent,#templateBody .mcnTextContent p{
  /*@editable*/font-size:16px !important;
  /*@editable*/line-height:150% !important;
  }
   
  } @media only screen and (max-width: 480px){
  /*
  @tab Mobile Styles
  @section Footer Text
  @tip Make the footer content text larger in size for better readability on small screens.
  */
  #templateFooter .mcnTextContent,#templateFooter .mcnTextContent p{
  /*@editable*/font-size:14px !important;
  /*@editable*/line-height:150% !important;
  }
   
  }</style></head>
  <body>
  <center>
  <table align="center" border="0" cellpadding="0" cellspacing="0" height="100%" width="100%" id="bodyTable">
  <tr>
  <td align="center" valign="top" id="bodyCell">
  <!-- BEGIN TEMPLATE // -->
  <!--[if gte mso 9]>
  <table align="center" border="0" cellspacing="0" cellpadding="0" width="600" style="width:600px;">
  <tr>
  <td align="center" valign="top" width="600" style="width:600px;">
  <![endif]-->
  <table border="0" cellpadding="0" cellspacing="0" width="100%" class="templateContainer">
  <tr>
  <td valign="top" id="templatePreheader"><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnTextBlock" style="min-width:100%;">
  <tbody class="mcnTextBlockOuter">
  <tr>
  <td valign="top" class="mcnTextBlockInner" style="padding-top:9px;">
  <!--[if mso]>
  <table align="left" border="0" cellspacing="0" cellpadding="0" width="100%" style="width:100%;">
  <tr>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="390" style="width:390px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:390px;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-left:18px; padding-bottom:9px; padding-right:18px;">
   
  <em>Educational Opportunities from AES</em>
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="210" style="width:210px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:210px;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-left:18px; padding-bottom:9px; padding-right:18px;">
   
  <a href="*|ARCHIVE|*" target="_blank">View this email in your browser</a>
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </tbody>
  </table></td>
  </tr>
  <tr>
  <td valign="top" id="templateHeader"><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnImageBlock" style="min-width:100%;">
  <tbody class="mcnImageBlockOuter">
  <tr>
  <td valign="top" style="padding:9px" class="mcnImageBlockInner">
  <table align="left" width="100%" border="0" cellpadding="0" cellspacing="0" class="mcnImageContentContainer" style="min-width:100%;">
  <tbody><tr>
  <td class="mcnImageContent" valign="top" style="padding-right: 9px; padding-left: 9px; padding-top: 0; padding-bottom: 0; text-align:center;">
   
   
  <img align="center" alt="" src="https://gallery.mailchimp.com/f1772c982a7930de0769135d3/images/ee9e808d-24c7-4303-8524-ad925c089073.jpg" width="564" style="max-width:585px; padding-bottom: 0; display: inline !important; vertical-align: bottom;" class="mcnImage">
   
   
  </td>
  </tr>
  </tbody></table>
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnDividerBlock" style="min-width:100%;">
  <tbody class="mcnDividerBlockOuter">
  <tr>
  <td class="mcnDividerBlockInner" style="min-width:100%; padding:18px;">
  <table class="mcnDividerContent" border="0" cellpadding="0" cellspacing="0" width="100%" style="min-width: 100%;border-top: 2px solid #EAEAEA;">
  <tbody><tr>
  <td>
  <span></span>
  </td>
  </tr>
  </tbody></table>
  <!--
  <td class="mcnDividerBlockInner" style="padding: 18px;">
  <hr class="mcnDividerContent" style="border-bottom-color:none; border-left-color:none; border-right-color:none; border-bottom-width:0; border-left-width:0; border-right-width:0; margin-top:0; margin-right:0; margin-bottom:0; margin-left:0;" />
  -->
  </td>
  </tr>
  </tbody>
  </table></td>
  </tr>
  <tr>
  <td valign="top">
  <table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" id="templateColumns">
  <tr>
  <td valign="top">
  <!--[if gte mso 9]>
  <table align="center" border="0" cellspacing="0" cellpadding="0" width="600" style="width:600px;">
  <tr>
  <td align="center" valign="top" width="400" style="width:400px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" width="400" id="templateBody">
  <tr>
  <td><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnTextBlock" style="min-width:100%;">
  <tbody class="mcnTextBlockOuter">
  <tr>
  <td valign="top" class="mcnTextBlockInner" style="padding-top:9px;">
  <!--[if mso]>
  <table align="left" border="0" cellspacing="0" cellpadding="0" width="100%" style="width:100%;">
  <tr>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="400" style="width:400px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:100%; min-width:100%;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-right:18px; padding-bottom:9px; padding-left:18px;">
   
  <h4 class="null" style="text-align: center;"><span style="color:#4B0082">New for 2017:</span></h4>
   
  <h4 class="null" style="text-align: center;"><span style="color:#4B0082">Self Assessment in Epilepsy Volume 4</span></h4>
   
  <p paraeid="{fad52124-a9f3-407c-9e5a-ca0dbfa6dfab}{171}" paraid="1573309381" style="text-align: left;"><span style="font-size:13px">The SAE Volume 4 (2017) contains 50 questions spanning the breadth of epilepsy diagnosis and treatment. <a href="http://aes.mycrowdwisdom.com/diweb/gateway/init/1/f/catalog*2Fitem*2Feid*2FEM17SAE04?utm_source=email&amp;utm_campaign=sae&amp;utm_medium=ednewslettertext&amp;utm_content=vol4" target="_blank">This online assessment activity</a> includes peer-reviewed questions with the rationale for each preferred response as well as annotated answers, including relevant citations from peer-reviewed publications.</span><br>
  &nbsp;</p>
   
  <p paraeid="{fad52124-a9f3-407c-9e5a-ca0dbfa6dfab}{171}" paraid="1573309381" style="text-align: center;"><span style="font-size:13px"><strong>Member Price:</strong> $49 USD | <strong>Non-Member Price:</strong> $99 USD</span></p>
   
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnButtonBlock" style="min-width:100%;">
  <tbody class="mcnButtonBlockOuter">
  <tr>
  <td style="padding-top:0; padding-right:18px; padding-bottom:18px; padding-left:18px;" valign="top" align="center" class="mcnButtonBlockInner">
  <table border="0" cellpadding="0" cellspacing="0" class="mcnButtonContentContainer" style="border-collapse: separate !important;border-radius: 3px;background-color: #4F148F;">
  <tbody>
  <tr>
  <td align="center" valign="middle" class="mcnButtonContent" style="font-family: Arial; font-size: 16px; padding: 15px;">
  <a class="mcnButton " title="Access Now" href="http://aes.mycrowdwisdom.com/diweb/gateway/init/1/f/catalog*2Fitem*2Feid*2FEM17SAE04?utm_source=email&amp;utm_campaign=sae&amp;utm_medium=ednewsletterbutton&amp;utm_content=vol4" target="_blank" style="font-weight: bold;letter-spacing: normal;line-height: 100%;text-align: center;text-decoration: none;color: #FFFFFF;">Access Now</a>
  </td>
  </tr>
  </tbody>
  </table>
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnTextBlock" style="min-width:100%;">
  <tbody class="mcnTextBlockOuter">
  <tr>
  <td valign="top" class="mcnTextBlockInner" style="padding-top:9px;">
  <!--[if mso]>
  <table align="left" border="0" cellspacing="0" cellpadding="0" width="100%" style="width:100%;">
  <tr>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="400" style="width:400px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:100%; min-width:100%;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-right:18px; padding-bottom:9px; padding-left:18px;">
   
  <div style="text-align: center;"><span style="font-size:11px"><span style="color:#696969"><em>Login Required</em></span></span></div>
   
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnTextBlock" style="min-width:100%;">
  <tbody class="mcnTextBlockOuter">
  <tr>
  <td valign="top" class="mcnTextBlockInner" style="padding-top:9px;">
  <!--[if mso]>
  <table align="left" border="0" cellspacing="0" cellpadding="0" width="100%" style="width:100%;">
  <tr>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="400" style="width:400px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:100%; min-width:100%;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-right:18px; padding-bottom:9px; padding-left:18px;">
   
  <span style="font-size:14px">This activity has been approved for&nbsp;<em>AMA PRA Category 1 Credit™</em>.</span>
   
  <h4 class="null" style="text-align: left;">&nbsp;</h4>
   
  <div><span style="font-size:12px"><span style="color:#696969">These activities will help to fulfill your </span><a href="http://abpn.com" target="_blank"><span style="color:#696969">Maintenance of Certification</span></a><span style="color:#696969"> (MOC) requirement to participate in a self-assessment activity. You can also use them as a study tool for the subspecialty certifying examination.&nbsp;</span></span></div>
   
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnTextBlock" style="min-width:100%;">
  <tbody class="mcnTextBlockOuter">
  <tr>
  <td valign="top" class="mcnTextBlockInner" style="padding-top:9px;">
  <!--[if mso]>
  <table align="left" border="0" cellspacing="0" cellpadding="0" width="100%" style="width:100%;">
  <tr>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="400" style="width:400px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:100%; min-width:100%;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-right:18px; padding-bottom:9px; padding-left:18px;">
   
  <div style="text-align: center;"><span style="font-size:13px">See all of the Society's <span>Self Assessment</span> activities <a href="https://www.aesnet.org/professional_education/self-assessment?utm_source=email&amp;utm_campaign=sae&amp;utm_medium=ednewslettertext&amp;utm_content=sa" target="_blank">here</a>.</span><br>
  &nbsp;</div>
   
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnDividerBlock" style="min-width:100%;">
  <tbody class="mcnDividerBlockOuter">
  <tr>
  <td class="mcnDividerBlockInner" style="min-width:100%; padding:18px;">
  <table class="mcnDividerContent" border="0" cellpadding="0" cellspacing="0" width="100%" style="min-width: 100%;border-top: 2px solid #EAEAEA;">
  <tbody><tr>
  <td>
  <span></span>
  </td>
  </tr>
  </tbody></table>
  <!--
  <td class="mcnDividerBlockInner" style="padding: 18px;">
  <hr class="mcnDividerContent" style="border-bottom-color:none; border-left-color:none; border-right-color:none; border-bottom-width:0; border-left-width:0; border-right-width:0; margin-top:0; margin-right:0; margin-bottom:0; margin-left:0;" />
  -->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnTextBlock" style="min-width:100%;">
  <tbody class="mcnTextBlockOuter">
  <tr>
  <td valign="top" class="mcnTextBlockInner" style="padding-top:9px;">
  <!--[if mso]>
  <table align="left" border="0" cellspacing="0" cellpadding="0" width="100%" style="width:100%;">
  <tr>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="400" style="width:400px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:100%; min-width:100%;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-right:18px; padding-bottom:9px; padding-left:18px;">
   
  <h3 class="null" style="text-align: center;"><span style="color:#4B0082">Now Available:<br>
  All 2016 Annual Meeting Recordings</span></h3>
   
  <div style="text-align: center;"><br>
  <em><span style="font-size:14px"><strong>Recordings of the 2016 Annual Meeting Symposia and the Annual Course are now available for on-demand streaming!&nbsp;</strong></span><br>
  <span style="font-size:11px">(Attendees receive all recordings for free.)</span></em><br>
  &nbsp;</div>
  <span style="font-size:14px">If you missed it in Houston, be sure to watch presentations from the <a href="https://www.pathlms.com/aes/courses/3824?utm_source=email&amp;utm_campaign=am16&amp;utm_medium=ednewslettertext&amp;utm_content=od" target="_blank">2016 Presidential Symposium</a>. Dr. Michael Privitera asked speakers to discuss how they see current trends and discoveries influencing the future of epilepsy diagnosis and treatment. Lectures include:</span>
   
  <ul>
  <li><span style="font-size:14px">Current and Future Approaches to Surgery and Devices for Epilepsy, Dennis Spencer, M.D.</span></li>
  <li><span style="font-size:14px">Harnessing the Power of Bioinformatics in Epilepsy, Tracy Glauser, M.D.</span></li>
  <li><span style="font-size:14px">Brain Imaging in Epilepsy Now and in the Future, Jerzy Szaflarski, M.D., Ph.D.</span></li>
  <li><span style="font-size:14px">Current and Future Trends in Development of Antiepileptic Drugs, Henrik Klitgaard, Ph.D.</span></li>
  <li><span style="font-size:14px">Genes and Signaling Pathways: Future Therapeutic Strategies, Peter Crino, M.D., Ph.D. <span style="color:#696969"><em>(The Fritz R. </em></span></span><span style="color:#696969"><span style="font-size:14px"><em>Dreifuss</em></span></span><span style="color:#696969"><span style="font-size:14px"><em> Lecture)</em></span></span></li>
  </ul>
  <br>
  &nbsp;
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnButtonBlock" style="min-width:100%;">
  <tbody class="mcnButtonBlockOuter">
  <tr>
  <td style="padding-top:0; padding-right:18px; padding-bottom:18px; padding-left:18px;" valign="top" align="center" class="mcnButtonBlockInner">
  <table border="0" cellpadding="0" cellspacing="0" class="mcnButtonContentContainer" style="border-collapse: separate !important;border-radius: 3px;background-color: #5C0DA5;">
  <tbody>
  <tr>
  <td align="center" valign="middle" class="mcnButtonContent" style="font-family: Arial; font-size: 16px; padding: 15px;">
  <a class="mcnButton " title="View the Entire List" href="https://www.pathlms.com/aes/categories/755/courses?utm_source=email&amp;utm_campaign=am16&amp;utm_medium=ednewsletterbutton&amp;utm_content=od" target="_blank" style="font-weight: bold;letter-spacing: normal;line-height: 100%;text-align: center;text-decoration: none;color: #FFFFFF;">View the Entire List</a>
  </td>
  </tr>
  </tbody>
  </table>
  </td>
  </tr>
  </tbody>
  </table></td>
  </tr>
  </table>
  <!--[if gte mso 9]>
  </td>
  <td align="center" valign="top" width="200" style="width:200px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" width="200" id="templateSidebar">
  <tr>
  <td valign="top"><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnTextBlock" style="min-width:100%;">
  <tbody class="mcnTextBlockOuter">
  <tr>
  <td valign="top" class="mcnTextBlockInner" style="padding-top:9px;">
  <!--[if mso]>
  <table align="left" border="0" cellspacing="0" cellpadding="0" width="100%" style="width:100%;">
  <tr>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="200" style="width:200px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:100%; min-width:100%;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-right:18px; padding-bottom:9px; padding-left:18px;">
   
  <div style="text-align: center;"><span style="font-size:16px"><strong>AES Self Assessment Activities:</strong></span><br>
  &nbsp;</div>
   
  <div style="text-align: left;"><strong><span style="color:#4B0082">[NEW] </span></strong>Self Assessment in Epilepsy, Diagnosis, and Interpretation Using EEG Monitoring (2017)<br>
  <br>
  Self Assessment in Epilepsy vol. 1 (2013)<br>
  <br>
  Self Assessment in Epilepsy vol. 2 (2014)<br>
  <br>
  Self Assessment in Epilepsy vol. 3 (2016)<br>
  <br>
  <strong><span style="color:#4B0082">[NEW]&nbsp;</span></strong>Self Assessment in Epilepsy vol. 4 (2017)<br>
  <br>
  Self Assessment in Professionalism (2016)<br>
  &nbsp;</div>
   
  <div style="text-align: center;"><span style="font-size:10px"><em>(login required to access)</em></span></div>
   
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnButtonBlock" style="min-width:100%;">
  <tbody class="mcnButtonBlockOuter">
  <tr>
  <td style="padding-top:0; padding-right:18px; padding-bottom:18px; padding-left:18px;" valign="top" align="center" class="mcnButtonBlockInner">
  <table border="0" cellpadding="0" cellspacing="0" class="mcnButtonContentContainer" style="border-collapse: separate !important;border-radius: 1px;background-color: #911159;">
  <tbody>
  <tr>
  <td align="center" valign="middle" class="mcnButtonContent" style="font-family: Arial; font-size: 12px; padding: 10px;">
  <a class="mcnButton " title="Access Now" href="http://aes.mycrowdwisdom.com/diweb/catalog/c/95/q/assessment/o/-d?utm_source=email&amp;utm_campaign=sa&amp;utm_medium=ednewsletterbutton&amp;utm_content=sa" target="_blank" style="font-weight: bold;letter-spacing: normal;line-height: 100%;text-align: center;text-decoration: none;color: #FFFFFF;">Access Now</a>
  </td>
  </tr>
  </tbody>
  </table>
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnDividerBlock" style="min-width:100%;">
  <tbody class="mcnDividerBlockOuter">
  <tr>
  <td class="mcnDividerBlockInner" style="min-width: 100%; padding: 10px 18px;">
  <table class="mcnDividerContent" border="0" cellpadding="0" cellspacing="0" width="100%" style="min-width: 100%;border-top: 1px solid #6231AD;">
  <tbody><tr>
  <td>
  <span></span>
  </td>
  </tr>
  </tbody></table>
  <!--
  <td class="mcnDividerBlockInner" style="padding: 18px;">
  <hr class="mcnDividerContent" style="border-bottom-color:none; border-left-color:none; border-right-color:none; border-bottom-width:0; border-left-width:0; border-right-width:0; margin-top:0; margin-right:0; margin-bottom:0; margin-left:0;" />
  -->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnTextBlock" style="min-width:100%;">
  <tbody class="mcnTextBlockOuter">
  <tr>
  <td valign="top" class="mcnTextBlockInner" style="padding-top:9px;">
  <!--[if mso]>
  <table align="left" border="0" cellspacing="0" cellpadding="0" width="100%" style="width:100%;">
  <tr>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="200" style="width:200px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:100%; min-width:100%;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-right:18px; padding-bottom:9px; padding-left:18px;">
   
  <div>
  <div style="text-align: center;"><span style="color:#444444"><strong><span style="font-size:16px">ABPN Epilepsy Certification Grandfathering Period Has Been Extended</span></strong></span></div>
  &nbsp;
   
  <p paraeid="{3b931687-ba75-4603-b232-ad4cbfc4f988}{11}" paraid="1660926240"><em>The “grandfathering” period for practice time required to qualify for ABPN certification in epilepsy has been extended from 2017 to 2018.</em><br>
  <br>
  <strong>Applications for the 2017 certification exam were due by April 10 (normal deadline) or May 10 (late deadline; $500 fee). For more information, visit </strong><a href="https://www.abpn.com/become-certified/taking-a-subspecialty-exam/epilepsy/" target="_blank">ABPN's website</a><strong>.</strong><br>
  &nbsp;</p>
   
  <p paraeid="{3b931687-ba75-4603-b232-ad4cbfc4f988}{11}" paraid="1660926240" style="text-align: center;"><strong>Important Dates:</strong><br>
  Late Deadline: May 10, 2017<br>
  Exam Dates: Oct&nbsp;16-20, 2017</p>
  </div>
   
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnDividerBlock" style="min-width:100%;">
  <tbody class="mcnDividerBlockOuter">
  <tr>
  <td class="mcnDividerBlockInner" style="min-width: 100%; padding: 10px 18px;">
  <table class="mcnDividerContent" border="0" cellpadding="0" cellspacing="0" width="100%" style="min-width: 100%;border-top: 1px solid #6231AD;">
  <tbody><tr>
  <td>
  <span></span>
  </td>
  </tr>
  </tbody></table>
  <!--
  <td class="mcnDividerBlockInner" style="padding: 18px;">
  <hr class="mcnDividerContent" style="border-bottom-color:none; border-left-color:none; border-right-color:none; border-bottom-width:0; border-left-width:0; border-right-width:0; margin-top:0; margin-right:0; margin-bottom:0; margin-left:0;" />
  -->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnTextBlock" style="min-width:100%;">
  <tbody class="mcnTextBlockOuter">
  <tr>
  <td valign="top" class="mcnTextBlockInner" style="padding-top:9px;">
  <!--[if mso]>
  <table align="left" border="0" cellspacing="0" cellpadding="0" width="100%" style="width:100%;">
  <tr>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="200" style="width:200px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:100%; min-width:100%;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-right:18px; padding-bottom:9px; padding-left:18px;">
   
  <div style="text-align: center;"><span style="font-size:16px"><strong>On-Demand Webinar:<br>
  Therapeutic Drug Monitoring of AEDs</strong></span><br>
  <br>
  <span style="font-size:11px"><span style="color:#696969"><em>Recorded on:<br>
  Tuesday, March 28, 2017</em><br>
  <br>
  Presenter:&nbsp;Timothy E. Welty, M.A., Pharm.D., FCCP<br>
  Moderator: Dennis J. Dlugos, M.D.</span></span><br>
  &nbsp;</div>
   
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnButtonBlock" style="min-width:100%;">
  <tbody class="mcnButtonBlockOuter">
  <tr>
  <td style="padding-top:0; padding-right:18px; padding-bottom:18px; padding-left:18px;" valign="top" align="center" class="mcnButtonBlockInner">
  <table border="0" cellpadding="0" cellspacing="0" class="mcnButtonContentContainer" style="border-collapse: separate !important;border-radius: 1px;background-color: #911159;">
  <tbody>
  <tr>
  <td align="center" valign="middle" class="mcnButtonContent" style="font-family: Arial; font-size: 12px; padding: 10px;">
  <a class="mcnButton " title="Access Now" href="https://www.pathlms.com/aes/courses/4181?utm_source=email&amp;utm_campaign=webinars&amp;utm_medium=ednewsletterbutton&amp;utm_content=od" target="_blank" style="font-weight: bold;letter-spacing: normal;line-height: 100%;text-align: center;text-decoration: none;color: #FFFFFF;">Access Now</a>
  </td>
  </tr>
  </tbody>
  </table>
  </td>
  </tr>
  </tbody>
  </table><table border="0" cellpadding="0" cellspacing="0" width="100%" class="mcnTextBlock" style="min-width:100%;">
  <tbody class="mcnTextBlockOuter">
  <tr>
  <td valign="top" class="mcnTextBlockInner" style="padding-top:9px;">
  <!--[if mso]>
  <table align="left" border="0" cellspacing="0" cellpadding="0" width="100%" style="width:100%;">
  <tr>
  <![endif]-->
   
  <!--[if mso]>
  <td valign="top" width="200" style="width:200px;">
  <![endif]-->
  <table align="left" border="0" cellpadding="0" cellspacing="0" style="max-width:100%; min-width:100%;" width="100%" class="mcnTextContentContainer">
  <tbody><tr>
   
  <td valign="top" class="mcnTextContent" style="padding-top:0; padding-right:18px; padding-bottom:9px; padding-left:18px;">
   
  <div style="text-align: center;">See a listing of all on-demand webinars <a href="https://www.pathlms.com/aes/categories/754/courses?utm_source=email&amp;utm_campaign=webinars&amp;utm_medium=ednewslettertext&amp;utm_content=od" target="_blank">here</a>.</div>
   
  </td>
  </tr>
  </tbody></table>
  <!--[if mso]>
  </td>
  <![endif]-->
   
  <!--[if mso]>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </tbody>
  </table></td>
  </tr>
  </table>
  <!--[if gte mso 9]>
  </td>
  </tr>
  </table>
  <![endif]-->
  </td>
  </tr>
  </table>
  </td>
  </tr>
  <tr>
  <td valign="top" id="templateFooter"></td>
  </tr>
  </table>
  <!--[if gte mso 9]>
  </td>
  </tr>
  </table>
  <![endif]-->
  <!-- // END TEMPLATE -->
  </td>
  </tr>
  </table>
  </center>
  </body>
  </html>

 

the FDA approved an important change to the Fycompa (perampanel) prescribing information. Perampanel is now approved as monotherapy for patients 12 years of age and older who have partial (focal)-onset seizures both with and without progression to generalized tonic-clonic seizures. This new, expanded FDA indication does not include monotherapy for primary generalized tonic-clonic seizures, where perampanel is still approved as adjunctive treatment.

This is the first antiepileptic drug (AED) to receive approval for monotherapy use under the FDA's new rule granting a monotherapy indication based solely on the results of randomized controlled trials of adjunctive therapy for partial (focal)-onset seizures.